FDA accepts second application for Ocular Therapeutix's drug-delivering implant

Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has accepted a new supplemental New Drug Application for its Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery.

The Bedford, Mass.-based company’s device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops.

Read the whole story on our sister site, Drug Delivery Business News

Building Better Companies at DeviceTalks Minnesota

DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:

Navigating the path to market
Reimbursement
Winning regulatory approval
Corporate culture
Entering global markets
Leadership

Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota.

Use code SAVE15 to save 15%!

REGISTER NOW